In FTO high cancer cells, including leukemia and glioma, R-2HG inhibited cancer cell proliferation/survival and promoted cell cycle arrest and apoptosis, while reversing drug resistance by targeting the FTO/m6A/MYC/CEBPA signaling pathway 124. Here, MYC is linked to cancer.